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SUMMARY 
National Surveillance of Dialysis-Associated Diseases in the United States, 1999 
! See summary of selected results (Table 1). 
! This survey was performed yearly during 1982-1997 and in 1999 by the Centers for 
Disease Control and Prevention (CDC) and the Health Care Financing Administration 
(HCFA). 
! Hepatitis B vaccine use.  During 1997-1999, the percent of patients vaccinated increased 
from 47% to 55% and the percent of staff vaccinated increased from 87% to 88%. 
! Influenza and pneumococcal pneumonia vaccines (data first collected in 1999). 
1999, an estimated 67% of patients had been vaccinated for influenza and 29% for 
pneumococcal pneumonia. 
In 
! Hepatitis C virus. In 1999, routine testing for antibody to hepatitis C virus (anti-HCV) 
was performed on staff at 36% of centers and on patients at 56% of centers. At centers 
testing, anti-HCV was found in 1.9% of staff and 8.9% of patients. 
! Vascular access. During 1995-1999, the percentage of patients who received dialysis 
through central catheters increased from 13% to 22%; this trend is worrisome since 
infections and antimicrobial use are higher in patients receiving dialysis through catheters. 
However, during the same period, the percentage of patients receiving dialysis through 
fistulas increased from 22% to 26%. 
! Reasons for the use of catheters (data first collected in 1999). In 1999, 26% of catheters 
were used for new patients awaiting an implanted access, 27% for established patients with 
a failed access awaiting a new implanted access, 42% as an access of last resort, and 7% 
for other reasons, including patient preference. 
! Vancomycin use. The median percentage of patients reported to have received 
vancomycin during December decreased from 5.6% in 1995 to 4.3% in 1999. 
! Vancomycin-resistant enterococcus (VRE). The percent of centers reporting one or 
more patients infected or colonized with VRE increased from 11.5% in 1995 to 34.1% in 
1999. 
! The Dialysis Surveillance Network.  Because of the importance of these issues, CDC 
developed a voluntary surveillance system that has been in operation since August 1999. 
See Appendix II for more details. 
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Table 1. Summary
 
National Surveillance of Dialysis-Associated Diseases, 1995-1999, United States
 
Category Unit of 
Measurement 
Year 
1995 1997 1999 
Centers responding to survey number of centers 2,647 3,077 3,483 
Reuse dialyzers % of centers 77 82 80 
Total staff, all centers (end of year) number of staff 43,465 50,321 52,368 
Hepatitis B vaccination, staff % of staff 82* 87* 88* 
Test staff for anti-HCV % of centers 16 25 36 
Anti-HCV prevalence, staff % of staff 2.0 1.6 1.9 
Total patients, all centers (end of year) number of patients 162,970 195,935 225,226 
Vascular access
 Arteriovenous graft 
% of patients 
65 60 52
 Arteriovenous fistula 22 23 26
 Central catheter 13 17 22 
Hepatitis B vaccination, patients % of patients 35* 47* 55* 
Influenza vaccination, patients estimated % of 
patients 
vaccinated 
- -­ 67 
Pneumococcal pneumonia vaccination, patients -­ -­ 29 
Test patients for anti-HCV % of centers 39 48 56 
Anti-HCV prevalence, patients % of patients 10.4 9.3 8.9 
HIV infection % of patients 1.4 1.3 1.4 
AIDS % of patients 0.7 0.6 0.5 
Vancomycin use, December % of patients, 
median 
5.6 4.5 4.3 
Vancomycin-resistant enterococcus (VRE) 
% of centers 
with $1 patients 
11.5 29.8 34.1 
Methicillin-resistant 
Staphylococcus aureus 
40 56 67 
Anti-HCV denotes antibody to hepatitis C virus; HIV denotes human immunodeficiency virus; AIDS denotes 
acquired immunodeficiency syndrome. 
* For 1997 and 1999, included patients treated, or staff members working, at the end of the year. For 1995, 
included staff and patients from throughout the year. 
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INTRODUCTION 
The Centers for Disease Control and Prevention (CDC) has been conducting surveillance 
of hemodialysis-associated hepatitis since the early 1970s (1), when CDC reported that the 
incidence of HBV infection among patients and staff during 1972-1974 had increased by more 
than 100%, to 6.2% and 5.2%, respectively. These early surveys had only a 50% to 65% response 
rate of centers listed by the National Dialysis Registry. In an effort to obtain a higher response 
rate, and thus more complete information, CDC initiated a cooperative program with the Health 
Care Financing Administration (HCFA) in 1976 that provided for a questionnaire from CDC to be 
included in HCFA's annual facility survey. As a result of this collaboration, the response rates to 
the CDC questionnaire now exceed 90%.
 Since collaboration with HCFA was begun, the CDC survey has been performed for 
calendar years 1976, 1980, 1982 to 1997, and 1999 (2-12). Other hemodialysis-associated 
diseases and practices not related to hepatitis have been included over the years, and the 
questionnaire is continually updated to collect data about hemodialysis practices and hemodialysis­
associated diseases of current interest and importance. The objectives of this yearly survey are to 
(a) determine the frequency with which certain hemodialysis practices are used, including 
measures designed to prevent disease, (b) determine the frequency of hemodialysis-associated 
complications and diseases, and (c) use this information to suggest further measures to prevent 
complications and disease in hemodialysis patients and staff. 
METHODS 
In conjunction with the annual facility survey performed by HCFA for calendar year 1999, 
CDC distributed a questionnaire (see Appendix I) by mail to all chronic hemodialysis centers 
licensed by HCFA. All responses were reviewed, and approximately 10% of centers that 
responded provided inaccurate or inconsistent responses and were contacted for clarification of 
responses. The survey covered: 
a. hemodialysis practices, reuse of disposable dialyzers, type of vascular access, 
procedures for cleaning and disinfection of dialysis equipment. 
b. use of hepatitis B virus, pneumococcal pneumonia, and influenza vaccines in 
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patients. 
c. the results of testing patients for hepatitis B surface antigen (HBsAg), antibody to 
HBsAg (anti-HBs), and antibody to hepatitis C virus (anti-HCV). 
d. the number of patients who received vancomycin in December 1999, and whether 
$1 patients with vancomycin-resistant enterococcus (VRE) or methicillin-resistant 
Staphylococcus aureus (MRSA) were treated during 1999. 
e. the number of patients with human immunodeficiency virus (HIV) infection. 
f. in staff members, receipt of hepatitis B vaccine, and testing for anti-HCV. 
Survey questions on hepatitis B vaccination and the prevalence of HIV infection/AIDS 
were changed for the 1997 and 1999 surveys, and referred only to patients treated or staff 
members who worked during a one-week period in December (in 1999, this was December 6-11) 
of the survey year; in previous years, the questions referred to patients and staff present in the unit 
at any time during the year. 
In 1999, the incidence of hepatitis B virus (HBV) infection was defined as the number of 
patients who became positive for HBsAg during 1999 divided by the number of patients treated at 
the facility during December 6-11, 1999; in effect, the number of patients treated during the one-
week period in December 1999 was used as an estimate of the average census at that dialysis 
center during 1999. In previous years, the denominator for this incidence rate was the total 
number of patients treated at the facility at any time during the year. 
The prevalence rates of chronic HBV infection and immunity were defined as the 
percentage of all patients or staff present in the facility during December 6-11, 1999, who were 
positive for HBsAg or anti-HBs, respectively. All patients or staff (regardless of their 
susceptibility to HBV infection) were included in calculations of the incidence and prevalence of 
HBV infection. Among groups of dialysis centers, the median percent of patients receiving 
vancomycin in December 1999 was calculated by weighting each dialysis center by the number of 
patients treated. 
Information on dialysis center location and ownership was obtained from the HCFA End 
Stage Renal Disease (ESRD) Facility Survey dataset. The results of the 1999 survey were 
compared to results from previous surveys. For administrative purposes, HCFA has designated 18 
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ESRD Networks, each composed of $1 U.S. states, districts or territories(13); to evaluate 
differences in practices and diseases among centers in different geographic regions, analyses were 
performed according to ESRD Network. 
Proportions were compared with the chi square or Fisher's exact test; when adjustment for 
confounding variables was required, the Mantel-Haenszel test or logistic regression was used. All 
p-values were two-tailed; a p-value of <0.05 was considered statistically significant. 
RESULTS AND DISCUSSION 
Questionnaires were returned by 3,483 (94%) of 3,668 centers. These 3,483 centers 
represented 225,226 patients and 52,368 staff members. During 1987-1999, the median number of 
patients per center increased from 40 to 56 and the median number of staff members per center 
increased from 12 to 13 (Table 2). 
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Table 2. Numbers of Hemodialysis Centers, Patients, and Staff Members Surveyed, 1985-1999, United States 
Year No. of Centers 
Patients Staff Members 
Total Patients 
Median per 
Center Total Staff 
Median per 
Center 
1985 1,250 62,172 –* 20,346 – 
1986 1,350 67,387 -­ 21,094 -­
1987 1,486 74,249 40 22,334 12 
1988 1,586 80,651 41 23,778 12 
1989 1,726 90,596 42 26,112 12 
1990 1,882 101,763 43 29,252 13 
1991 2,046 116,651 46 33,079 13 
1992 2,170 128,264 49 36,000 14 
1993 2,304 135,798 49 37,992 14 
1994 2,449 149,743 51 40,951 14 
1995 2,647 162,970 51 43,465 14 
1996 2,808 177,324 53 47,215 14 
1997 3,077 195,935 54 50,321 14 
1999 3,483 225,226 56 52,368 13 
The numbers of patients and staff members reflect the numbers present during a one-week period in December of 
the year. 
* Data not available. 
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During 1985-1999, the proportion of freestanding (i.e., located outside the hospital) centers 
increased from 56% to 80%, and the proportion of centers operating for profit increased from 46% 
to 75% (Table 3). 
Table 3. Location and Ownership of Hemodialysis Centers, 1985-1999, United States 
Year 
Location Ownership 
Hospital Freestanding Profit Nonprofit Government 
percent of hemodialysis centers 
1985 44 56 46 44 11 
1986 42 58 49 41 10 
1987 39 61 51 40 9 
1988 37 63 53 39 8 
1989 35 65 55 38 7 
1990 34 66 56 37 7 
1991 35 65 56 35 9 
1992 33 67 57 34 9 
1993 31 69 62 32 6 
1994 29 71 62 31 6 
1995 27 73 63 30 7 
1996 26 74 66 28 6 
1997 23 77 70 25 5 
1999 20 80 75 21 4 
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Dialyzer Types 
During December 6-11, 1999, the most common dialyzer types were high flux polysulfone (e.g., 
F60, F80, 50% of patients) and low flux polysulfone (e.g., F5, F8; 20.9% of patients) (Table 4).
 Table 4. Dialyzer Types, December 6-11, 1999, United States 
Percent of Patients 
Dialyzer Type Treated With 
High flux polysulfone 50.0 
Low flux polysulfone 20.9 
Cellulose acetate 11.5 
Cellulose triacetate 8.4 
Regenerated cellulose, 6.5 
cuprophan 
Hemophan 0.9 
PMMA 0.2 
Other 3.4 
. 
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Dialyzer Reuse 
During 1976-1997, the percentage of centers that reported reuse of disposable dialyzers 
increased from 18% to 82%, but decreased slightly to 80% in 1999 (Table 5). Although dialyzer 
reuse has been implicated in numerous outbreaks, this practice is safe if performed according to 
recognized protocols (14,15). 
Table 5. Hemodialysis Centers Having Dialyzer Reuse Programs, 1976-1999, United States 
Year No. of Centers 
No. (%) Reusing 
Dialyzers 
1976 750 135 (18) 
1980 956 179 (19) 
1982 1,015 435 (43) 
1983 1,120 579 (52) 
1984 1,201 693 (58) 
1985 1,250 764 (61) 
1986 1,350 855 (63) 
1987 1,486 948 (64) 
1988 1,586 1,058 (67) 
1989 1,726 1,172 (68) 
1990 1,882 1,310 (70) 
1991 2,046 1,453 (71) 
1992 2,170 1,569 (72) 
1993 2,304 1,688 (73) 
1994 2,449 1,835 (75) 
1995 2,647 2,048 (77) 
1996 2,808 2,261 (81) 
1997 3,077 2,523 (82) 
1999 3,478 2,788 (80) 
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Methods Used for Reprocessing Dialyzers 
During 1983-1999, the proportion of centers using formaldehyde for reprocessing dialyzers 
decreased from 94% to 33%, while the proportion using a peracetic acid product increased from 
5% to 58% (Table 6). In 1999, 3% of centers used heat to disinfect dialyzers between reuses. 
Table 6. Methods for Reprocessing Dialyzers in Hemodialysis Centers, 1983-1999, United States 
Year 
Percent of Centers Using Method 
Formaldehyde Peracetic Acid Glutaraldehyde Heat 
1983 94 5 <1 -­
1984 86 12 3 -­
1985 80 17 3 -­
1986 69 28 3 -­
1987 62 34 4 -­
1988 54 40 6 -­
1989 47 46 7 -­
1990 43 49 8 -­
1991 42 50 9 -­
1992 40 52 8 <1 
1993 40 51 8 1 
1994 40 52 7 1 
1995 38 54 7 1 
1996 36 54 7 3 
1997 34 56 7 3 
1999 33 58 6 3 
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Vascular Access Types 
During December 6-11, 1999, 51.9% of patients received dialysis through an arteriovenous 
graft, 26.0% through an arteriovenous fistula, and 22.2% through a temporary or permanent central 
catheter (Table 7). Since 1995, the percent of patients receiving dialysis through catheters 
increased from 12.7% to 22.2%. 
In 1999, 25.6% of catheters were used for new patients awaiting an implanted access (i.e., 
a fistula or graft), 27.3% for established patients with a failed access awaiting a new implanted 
access, 42.2% as an access of last resort, and 6.6% for other reasons, including patient preference. 
Among the 18 ESRD networks designated by HCFA (see Methods), use of fistulas (the 
most desirable access type) ranged from 18.3% to 38.2% (Table 8). The estimated risk of access-
related bacteremia was calculated by using rates measured in the Dialysis Surveillance 
Network(16), a voluntary surveillance system for monitoring bacterial infections and related events 
in hemodialysis patients (Appendix II); the rates used for this calculation were 0.22 access-related 
bacteremias per 100 patient-months for fistulas, 0.48 for grafts, 5.25 for noncuffed catheters, and 
8.85 for cuffed catheters (unpublished data, CDC). Network 17 had the lowest estimated risk and 
Network 9 the highest; note that the estimated risk of vascular access infection is most closely 
related to the percentage of patients receiving dialysis through cuffed catheters. 
Table 7. Types of Vascular Access Used for Hemodialysis, 1995-1999, United States. 
Year 
Number of 
Patients 
Percent of Patients Receiving Dialysis Through 
Fistula Graft Catheter 
1995 153,320 22.2 65.1 12.7 
1996 176,609 22.1 62.9 14.9 
1997 195,588 22.8 59.7 17.5 
1999 225,226 26.0 51.9 22.2 
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Table 8. Vascular Access Types by End Stage Renal Disease (ESRD) Network, December 1999, United States 
ESRD 
Network 
States, Districts, 
or Territories 
No. of 
Patients 
Percent of Patients Receiving Dialysis 
Through 
Estimated 
Risk of Access-
Related 
Bacteremia* 
Fistula Graft 
Noncuffed 
Catheter 
Cuffed 
Catheter 
17 AS, GU, HI, CA (northern) 11,283 28.1 56.1 3.8 11.9 1.6 
18 CA (southern) 16,605 23.4 60.3 3.3 13.4 1.7 
14 TX 18,825 18.3 64.5 2.4 14.8 1.8 
8 AL, MS, TN 13,011 19.3 63.0 3.3 14.6 1.8 
2 NY 17,041 36.4 44.8 2.2 16.8 1.9 
16 AK, ID, MT, OR, WA 5,392 35.8 45.7 0.9 17.7 1.9 
15 AZ, CO, NM, NV, UT, WY 8,235 31.5 48.1 2.2 18.3 2.0 
6 GA, NC, SC 20,418 23.1 55.2 3.0 19.0 2.2 
5 DC, MD, VA, WV 14,637 21.0 56.4 3.7 19.0 2.2 
1 CT, MA, ME, NH, RI, VT 8,284 38.2 38.7 3.1 20.0 2.2 
13 AR, LA, OK 10,330 21.2 55.2 3.4 20.2 2.3 
11 MI, MN, ND, SD, WI 13,401 25.7 49.4 4.1 21.1 2.4 
10 IL 9,841 25.2 48.9 5.0 21.1 2.4 
7 FL 13,167 26.9 47.0 3.5 22.8 2.5 
3 NJ, PR 10,331 31.0 40.9 6.9 21.2 2.5 
12 IA, KS, MO, NE 7,136 26.7 46.4 2.4 24.5 2.6 
4 DE, PA 10,965 26.7 45.7 2.3 25.4 2.6 
9 IN, KY, OH 15,967 25.5 46.5 2.5 25.5 2.7 
All 224,869 26.0 51.9 3.2 19.0 2.2 
AS denotes American Samoa, GU denotes Guam. 
* Estimated vascular access-related bacteremias per 100 patient-months. See text for details of the calculation. 
Rows are sorted by this estimate. 
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Use of Pneumococcal Vaccine 
In 1999, pneumococcal vaccine was offered to patients at 64.5% of centers, which 
included 18.4% of centers with <25% of patients vaccinated, 10.9% with 25-49% vaccinated, 
11.0% with 50-74% vaccinated, 17.1% with $75% vaccinated, and 7.1% with percent vaccinated 
unknown. 
The percent of patients vaccinated was estimated by assuming that 0% of patients were 
vaccinated at centers not offering the vaccine, 12.5% were vaccinated at centers with <25% 
vaccinated, 37.5% at centers with 25-49% vaccinated, 67.5% at centers with 50-74% vaccinated, 
and 87.5% at centers with $75% vaccinated. Overall, the estimated percent vaccinated was 28.9% 
(range 12.5%-41.6% among the ESRD Networks, Table 9). 
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Table 9. Use of Pneumococcal Vaccine In Patients by End Stage Renal Disease (ESRD) Network, 1999, United 
States 
ESRD 
Network States, Districts, or Territories 
No. of 
Centers
 Offer Vaccine to 
Patients (% of Centers) 
Estimated Percentage of 
Patients Vaccinated 
17 AS, GU, HI, CA (northern) 137 32.1 12.5 
3 NJ, PR 111 60.4 18.1 
18 CA (southern) 193 50.3 20.6 
6 GA, NC, SC 323 55.4 21.8 
13 AR, LA, OK 222 57.7 24.5 
5 DC, MD, VA, WV 249 61.8 27.0 
10 IL 109 65.1 28.8 
1 CT, MA, ME, NH, RI, VT 119 69.7 28.9 
15 AZ, CO, NM, NV, UT, WY 140 59.3 29.8 
7 FL 229 72.5 30.1 
8 AL, MS, TN 243 68.7 30.2 
16 AK, ID, MT, OR, WA 100 59.1 32.2 
2 NY 189 66.1 33.8 
14 TX 257 72.8 34.3 
4 DE, PA 188 72.3 34.7 
9 IN, KY, OH 243 67.5 37.4 
11 MI, MN, ND, SD, WI 257 80.5 38.1 
12 IA, KS, MO, NE 161 73.9 41.6 
All 3,474 64.5 28.9 
AS denotes American Samoa, GU denotes Guam.
 
Rows are sorted by estimated percentage of patients vaccinated.
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Use of Influenza Vaccine 
In 1999, influenza vaccine was offered to patients at 95.1% of centers, which included 
4.4% of centers with <25% of patients vaccinated, 9.6% with 25-49% vaccinated, 24.5% with 50­
74% vaccinated, 53.3% with $75% vaccinated, and 3.3% with percent vaccinated unknown 
(Table 10). The percent of patients vaccinated was estimated using methods similar to that 
outlined under “Use of Pneumococcal Vaccine.” Overall, the estimated percent vaccinated was 
67.4% (range 54.9-74.7% among the ESRD networks, Table 10). 
Table 10. Use of Influenza Vaccine in Patients by End Stage Renal Disease (ESRD) Network, 1999, United States 
ESRD 
Network States, Districts, or Territories 
No. of 
Centers 
Offer Vaccine to 
Patients (% of Centers) 
Estimated Percentage of 
Patients Vaccinated 
17 AS, GU, HI, CA (northern) 137 78.1 54.9 
10 IL 108 94.4 56.6 
16 AK, ID, MT, OR, WA 100 78.0 57.0 
7 FL 229 90.8 58.0 
3 NJ, PR 111 98.2 59.2 
18 CA (southern) 195 95.4 63.2 
5 DC, MD, VA, WV 250 89.6 64.9 
6 GA, NC, SC 326 95.4 68.4 
8 AL, MS, TN 244 98.8 69.0 
2 NY 191 96.3 69.7 
1 CT, MA, ME, NH, RI, VT 119 99.2 71.2 
11 MI, MN, ND, SD, WI 257 98.4 71.4 
13 AR, LA, OK 222 95.0 72.3 
9 IN, KY, OH 243 99.6 72.3 
4 DE, PA 187 99.5 73.6 
15 AZ, CO, NM, NV, UT, WY 141 96.5 74.5 
12 IA, KS, MO, NE 161 95.7 74.6 
14 TX 256 100.0 74.7 
All 3481 95.1 67.4 
AS denotes American Samoa, GU denotes Guam.
 
Rows are sorted by estimated percentage of patients vaccinated
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Use of Hepatitis B Vaccine 
In 1999, policies for vaccination of chronic hemodialysis patients were as follows: 94.6% 
of centers offered vaccine to patients; in 1.7% of centers vaccine was offered at individual 
physician’s offices; 2.2% of centers did not offer vaccine to patients; and 1.6% of centers reported 
other policies. 
During 1983-1999, the proportion who had ever received at least three doses of hepatitis B 
vaccine increased from 5% to 55% among patients and from 26% to 88% among staff (Table 11). 
Note that the survey questions on vaccination of patients and staff were changed for the 1997 and 
1999 surveys. During 1983-1996, the percent of patients vaccinated was calculated as the number 
of vaccinated patients treated at any time during the year divided by the total number of patients 
treated at any time during the year. In 1997 and 1999, the percent of patients vaccinated was 
calculated as the number of vaccinated patients who were present during a one-week period in 
December divided by the total number of patients present during the same one-week period in 
December. Similar methods were used to calculate the percents of staff vaccinated during the two 
time periods (1983-1996 vs 1997-1999). The vaccination data may be more accurate for 1997 and 
1999 than for previous years, since determination of vaccine status in December of the year, at the 
time the survey is completed, should be more accurate than determining vaccine status for patients 
treated (or staff members who worked) at any time during the year, as was requested in previous 
surveys. 
19 
Table 11. Use of Hepatitis B Vaccine in Hemodialysis Centers, 1983-1999, United States 
Year 
No. (%) Ever Receiving $3 Doses of Vaccine 
Patients Staff Members 
1983 3,619 ( 5.4) 5,670 (26.1) 
1984 4,495 ( 6.0) 7,181 (31.6) 
1985 6,290 ( 7.8) 8,521 (35.5) 
1986 8,815 (10.1) 9,877 (39.4) 
1987 12,270 (12.8) 11,316 (41.9) 
1988 17,019 (15.8) 12,949 (45.5) 
1989 21,623 (17.6) 15,578 (48.0) 
1990 24,260 (18.2) 19,311 (53.0) 
1991 25,397 (16.9) 22,499 (56.1) 
1992 37,459 (23.6) 30,069 (69.4) 
1993 47,183 (28.8) 34,885 (76.1) 
1994 61,492 (31.0) 40,008 (79.6) 
1995 74,217 (35.0) 44,542 (82.4) 
1996 79,133 (36.0) 48,817 (81.9) 
1997* 87,749 (46.7) 43,341 (86.6) 
1999* 116,920 (55.3) 45,735 (88.5) 
* Methods differed in 1983-1996 vs 1997-1999 (see text for details). 
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Among the ESRD networks, hepatitis B vaccination among patients in 1999 varied from 
38.8% to 66.7% (Table 12). The largest absolute increase in vaccination during 1997-1999 
occurred in ESRD network 18. 
Table 12. Use of Hepatitis B Vaccine in Hemodialysis Patients by End Stage Renal Disease (ESRD) Network, 
1995-1997, United States 
ESRD 
Network States, Districts, or Territories 
Percent Vaccinated Absolute 
Change1997 1999 
10 IL 31.5 38.8 7.3 
3 NJ, PR 37.4 41.5 4.1 
2 NY 36.5 43.7 7.2 
18 CA (southern) 29.9 52.2 22.3 
5 DC, MD, VA, WV 45.5 52.6 7.1 
17 AS, GU, HI, CA (northern) 39.0 54.7 15.7 
15 AZ, CO, NM, NV, UT, WY 42.8 56.2 13.4 
7 FL 52.0 56.4 4.4 
9 IN, KY, OH 47.7 57.2 9.5 
1 CT, MA, ME, NH, RI, VT 47.2 57.3 10.1 
11 MI, MN, ND, SD, WI 54.1 57.4 3.3 
6 GA, NC, SC 54.5 57.6 3.1 
13 AR, LA, OK 50.9 57.6 6.7 
4 DE, PA 53.0 58.o 5.0 
8 AL, MS, TN 53.7 61.7 8.0 
16 AK, ID, MT, OR, WA 58.0 62.5 4.5 
14 TX 55.0 65.2 10.2 
12 IA, KS, MO, NE 55.2 66.7 11.5 
All 46.7 55.3 8.6 
AS denotes American Samoa, GU denotes Guam. 
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Prevalence of Antibody to Hepatitis B Surface Antigen (anti-HBs) 
During 1980-1999, the prevalence of anti-HBs among patients increased from 11.3% to 
36.8% (Table 13). The presence of anti-HBs indicates immunity to HBV infection, either from 
vaccination or as a result of recovery from infection with natural infection (17). 
Table 13. Prevalence of Antibody to Hepatitis B Surface Antigen in Hemodialysis Patients and Staff, 1980-1999, 
United States 
Patients Staff Members 
Year Number Tested Prevalence (%) Number Tested Prevalence (%) 
1980 43,796 11.3 15,603 16.1 
1982* 49,275 12.3 16,235 18,1 
1983 54,343 18.3 18,714 39,2 
1984 60,782 19.5 19,793 43.6 
1985 62,172 17.7 20,346 45.9 
1986 59,425 17.9 20,456 47.4 
1987 67,387 18.3 21,761 49.6 
1988 71,262 19.9 23,012 53.6 
1989 81,672 19.1 25,355 54.0 
1990 90,661 19.7 28,470 58.1 
1991 101,888 21.2 31,872 62.7 
1992 102,337 24.2 32,916 70.4 
1993 114,528 28.7 35,589 78.1 
1994 130,798 28.9 36,804 78.4 
1995 144,607 30.8 38,627 79.2 
1996 158,545 32.0 40,328 77.6 
1997 163,937 33.3 38,638 78.1 
1999 207,293 36.8 Not collected Not collected 
* Hepatitis B vaccine introduced 
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Incidence and Prevalence of HBV Infection 
In 1999, 80.4% of centers reported screening susceptible patients monthly for HBsAg, 
0.7% bimonthly, 13.2% quarterly, 4.2% semiannually, and 1.4% other or none. 
During 1976-1999, the incidence of HBV infection in patients decreased from 4.4% to 
0.06%, with the largest decline occurring during 1976-1980 (Table 14). Note that in 1999 the 
denominator for the HBsAg incidence rate was the number of patients treated during a one-week 
period in December of the year, while in prior years it was the number of patients treated 
throughout the year. 
During 1976-1999, the prevalence of HBsAg-positivity among patients declined from 
7.8% to 0.9% (Table 14). 
In 1999, 3.3% of centers reported $1 patients with newly acquired (incident) HBV 
infection, 24.1% of centers reported $1 patients with chronic (prevalent) HBV infection, and 
25.5% of centers reported $1 patients with either acute or chronic HBV infection. 
This national surveillance project was initiated primarily because of the high incidence of 
HBV infection reported among hemodialysis patients and staff in the early 1970s (1). 
Hemodialysis patients may acquire HBV infection from community sources or from transmission 
in hemodialysis centers due to inadequate infection control precautions (18-20) or to accidental 
breaks in technique (21). Factors contributing to the decline in HBV infection since the 1970s 
have been previously reviewed (9). 
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Table 14. Incidence and Prevalence of Hepatitis B Virus Infection in Hemodialysis Patients, 1976-1999, United 
States 
Year 
Incidence Prevalence 
Total Patients Incidence (%) Total Patients Prevalence (%) 
1976 33,875 3.0 22,876 7.8 
1980 62,723 1.0 43,796 3.8 
1982 66,326 0.5 49,275 2.7 
1983 67,229 0.5 54,343 2.4 
1984 76,327 0.3 60,782 2.3 
1985 80,151 0.3 62,172 2.1 
1986 87,505 0.3 67,387 1.9 
1987 97,225 0.2 74,249 1.7 
1988 107,804 0.2 80,651 1.5 
1989 122,734 0.1 90,596 1.4 
1990 140,608 0.2 101,763 1.2 
1991 155,877 0.2 116,651 1.3 
1992 170,028 0.1 128,264 1.2 
1993 180,341 0.1 135,798 1.2 
1994 206,884 0.1 149,743 1.1 
1995 224,954 0.06 162,970 1.1 
1996 229,527 0.08 177,324 1.1 
1997 253,001 0.05 195,935 0.9 
1999 225,226* 0.06 225,226 0.9 
* Denominator changed for 1999 survey. See text. 
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Hepatitis C 
In 1999, 56% of centers tested patients for anti-HCV, and the prevalence of anti-HCV at 
these centers was 8.9%; 36% of centers tested staff for anti-HCV, and the prevalence of anti-HCV 
at these centers was 1.9% (Table 15). Among centers that tested for anti-HCV, 12.2% reported 
having $1 patients who became anti-HCV positive in 1999 (i.e., tested positive for anti-HCV in 
1999 and had previously tested negative). 
Anti-HCV prevalence among patients was similar at centers that reused (8.9%) and did not 
reuse (8.5%) dialyzers (p=0.6 controlling for center size). Anti-HCV prevalence among staff was 
similar at centers that reused (2.0%) and did not reuse (1.8%) dialyzers (p=0.4). 
Among centers that reused dialyzers, 1,973 (72.4%) reused them on patients that were anti-
HCV positive, 406 (14.9%) did not reuse them on anti-HCV positive patients, and 348 (12.8%) 
did not have any anti-HCV-positive patients. The prevalence of anti-HCV was higher at centers 
that reused vs those that did not reuse dialyzers on anti-HCV-positive patients (9.4% vs 7.9%, 
p=0.012 controlling for center size and ESRD network). The percent of centers with $1 patients 
who became anti-HCV positive in 1999 was higher among centers that reused dialyzers on anti-
HCV positive patients (13.8%) than on centers that did not (10.1%, p=0.1), but the difference was 
not statistically significant. Since reprocessed dialyzers are reused on the same patient, it is unclear 
why reuse would be associated with higher rates of HCV infection among patients. This 
association could be due to unmeasured confounding factors or related to environmental 
contamination resulting from improper handling (e.g., transport of used dialyzers to a reprocessing 
area without placing them in leakproof containers). 
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Table 15. Antibody to Hepatitis C Virus Testing and Prevalence among Hemodialysis Patients and Staff, 1992­
1999, United States 
Group Year 
% of Centers 
Testing 
Total 
Tested 
No. (%) 
Positive 
Patients 1992 22 27,086 2,202 (8.1) 
1993 29 37,654 3,654 (9.7) 
1994 34 50,438 5,306 (10.5) 
1995 39 61,400 6,362 (10.4) 
1996 44 75,601 7,652 (10.1) 
1997 48 91,098 8,434 (9.3) 
1999 56 120,871 10,726 (8.9) 
Staff 1992 10 2,889 45 (1.6) 
1993 15 4,825 75 (1.6) 
1994 16 5,679 106 (1.9) 
1995 16 6,238 122 (2.0) 
1996 20 8,472 113 (1.3) 
1997 25 11,649 190 (1.6) 
1999 36 16,804 327 (1.9) 
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Among the ESRD networks, anti-HCV prevalence ranged from to 5.6 to 11.3% (Table 
16). 
Table 16. Prevalence of Antibody to Hepatitis C Virus (anti-HCV) Among Hemodialysis Patients by End Stage 
Renal Disease (ESRD) Network, 1999, United States 
ESRD 
Network 
States, Districts, or 
Territories 
Total Tested Anti-HCV Positive 
(%) 
2 NY 11,515 11.3 
5 DC, MD, VA, WV 8,369 11.2 
14 TX 11,129 10.6 
3 NJ, PR 5,358 10.3 
13 AR, LA, OK 6,497 9.9 
4 DE, PA 6,348 9.8 
11 MI, MN, ND, SD, WI 6,588 9.3 
7 FL 7,778 8.8 
8 AL, MS, TN 7,038 8.3 
17 AS, GU, HI, CA (northern) 6,258 8.3 
12 IA, KS, MO, NE 2,900 8.2 
18 CA (southern) 8,096 7.6 
6 GA, NC, SC 12,174 7.4 
1 CT, MA, ME, NH, RI, VT 4,538 7.0 
16 AK, ID, MT, OR, WA 2,561 6.8 
10 IL 3,571 6.7 
15 AZ, CO, NM, NV, UT, WY 3,965 6.7 
9 IN, KY, OH 6,142 5.6 
All 120,871 8.9 
AS denotes American Samoa, GU denotes Guam. 
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Place of Preparation of Injectable Medications 
In 1999, medications from multidose vials were most commonly drawn into syringes in 
preparation for patient administration in a separate medication room or in a medication area 
separate from the dialysis stations (72.3% of centers), at the dialysis stations (10% of centers), or 
on a medication cart which is wheeled from patient dialysis station to dialysis station (17.8% of 
centers). 
The place where medications were drawn up was not associated with HBV incidence. 
However, use of a medication cart was associated with a higher anti-HCV prevalence and with a 
larger percent of centers with $1 patients who became anti-HCV positive in 1999 (Table 17). 
Table 17. Place Where Injectable Medications Were Prepared and Association with Hepatitis B Virus and Hepatitis 
C Virus Infection, 1999, United States 
Place Where Medication 
Drawn Up Into Syringe 
HBsAg Incidence, No. 
(%) of Patients 
Anti-HCV Prevalence, 
No. (%) of Patients* 
Had Patients Who 
Became Anti-HCV 
Positive in 1999, 
No. (%) of Centers* 
Separate medication 
room or area 
87 (0.059) 6,898 (8.6) 145 (10.3) 
Dialysis station 16 (0.066) 1,178 (9.1) 23 (11.2) 
Medication cart 30 (0.061) 2,623 (9.7)† 56 (15.8)† 
HBsAg denotes hepatitis B surface antigen, anti-HCV denotes antibody to hepatitis C virus. 
* Analysis limited to centers that test for anti-HCV. 
† P<0.05 compared with separate medication room. 
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Vancomycin Use 
The median percent of patients receiving vancomycin in December decreased from 5.6% 
in 1995 to 4.3% in 1999 (Table 18). In 1999, vancomycin use varied among the ESRD networks 
from 2.4% of patients in network 17 to 5.8% of patients in network 7 (Table 19). 
Table 18. Receipt of Vancomycin by Chronic Hemodialysis Patients, by Year, 1995-1999, United States 
Year 
Percent of Patients Receiving 
Vancomyin During December 
(median) 
1995 5.6 
1996 5.1 
1997 4.5 
1999 4.3 
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Table 19. Receipt of Vancomycin by Chronic Hemodialysis Patients by End Stage Renal Disease (ESRD) 
Network, December 1997 and 1999, United States 
ESRD 
Network States, Districts, or Territories 
Total Centers 
in 1999 
Received Vancomycin* Absolute 
Change1997 1999 
17 AS, GU, HI, CA (northern) 136 2.7 2.4 -0.3 
18 CA (southern) 180 3.5 2.7 -0.8 
16 AK, ID, MT, OR, WA 100 3.4 3.8 0.4 
11 MI, MN, ND, SD, WI 245 4.5 3.9 -0.6 
8 AL, MS, TN 223 4.0 4.0 0 
14 TX 245 3.4 4.0 0.6 
4 DE, PA 180 4.5 4.3 -0.2 
1 CT, MA, ME, NH, RI, VT 115 4.5 4.4 -0.1 
5 DC, MD, VA, WV 243 4.7 4.4 -0.3 
6 GA, NC, SC 295 4.5 4.4 -0.1 
2 NY 180 5.6 4.5 -1.1 
9 IN, KY, OH 233 5.5 4.6 -0.9 
12 IA, KS, MO, NE 157 5.0 4.6 -0.4 
15 AZ, CO, NM, NV, UT, WY 133 3.9 4.7 0.8 
10 IL 100 4.4 5.0 0.6 
13 AR, LA, OK 210 5.4 5.1 -0.3 
3 NJ, PR 111 6.9 5.7 -1.2 
7 FL 215 6.1 5.8 -0.3 
All 3,305 4.5 4.3 -0.2 
AS denotes American Samoa, GU denotes Guam. 
* Median percent of patients receiving vancomycin in December of 1997 or 1999 (rows are sorted on this value for 
1999). 
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Antimicrobial Use Policies 
In 1999, 93.6% of centers reported using $1 measures to encourage judicious antimicrobial 
use. Antimicrobial use policies included: the reason for the antimicrobial must be recorded in the 
patient’s chart or on an order form, 63.9% of centers; a written policy on antimicrobial use, 41.7% 
of centers; automatic stop order (i.e., antimicrobials must be reordered at intervals), 30.8% of 
centers; formulary restriction (i.e., only selected antimicrobials are available), 30.5% of centers; 
and approval needed for certain antimicrobials, 23.6% of centers. 
The median percentage of patients receiving vancomycin in December 1999 was slightly 
lower at centers having a written policy on antimicrobial use (4.1%) than at centers not having 
such a policy (4.5%, p=0.048). There were no significant differences in vancomycin use 
associated with other antimicrobial use measures (data not shown). 
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Vancomycin-Resistant Enterococci (VRE) 
In 1999, the number of patients with known VRE was as follows: no known patients with 
VRE, 65.9% of centers; 1-4 patients with VRE, 31.6% of centers; 5-9 patients with VRE, 1.9% of 
centers; and $10 patients with VRE, 0.5% of centers. At centers having $1 VRE-positive 
patients, VRE-positive patients were never treated in a separate room at 64.4% of centers, 
sometimes in a separate room at 13.5% of centers, and always in a separate room at 22.2% of 
centers. Rectal swab or stool cultures to check for VRE were done at 6% of centers. 
The percentage of centers reporting $1 patients with VRE increased from 11.5% in 1995 
to 34.1% in 1999 (Table 20). Among the ESRD networks, reporting of VRE varied from 14.0% 
(network 16) to 62.1% (network 1; Table 21). 
The data reported here on treatment of VRE patients are limited in that the survey does not 
distinguish between clinical infection and colonization (i.e., positive culture for the organism 
without invasive infection). Centers that perform surveillance for VRE with stool or rectal 
cultures, or that treat patients from hospitals where such culturing is done, would be more likely to 
report VRE-colonized patients, introducing “surveillance bias.” 
Table 20. Reporting of One or More Patients with Vancomycin-Resistant Enterococci (VRE), by Year, 1995-1999, 
United States 
Year Number of 
Centers 
Number (%) of Centers Reporting 
VRE Patients 
1995 2,634 303 (11.5) 
1996 2,801 596 (21.3) 
1997 3,077 918 (29.8) 
1999 3,462 1,180 (34.1) 
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Table 21. Reporting of One or More Patients with Vancomycin-Resistant Enterococci (VRE), by ESRD Network, 
1999, United States 
ESRD 
Network States, Districts, or Territories 
Percent of Centers 
Reporting VRE 
Absolute 
Change 
1997 1999 
16 AK, ID, MT, OR, WA 20.2 14.0 -6.2 
8 AL, MS, TN 14.8 17.7 2.9 
7 FL 13.3 19.7 6.4 
13 AR, LA, OK 14.8 20.3 5.5 
6 GA, NC, SC 20.8 25.8 5.0 
14 TX 20.2 29.2 9.0 
17 AS, GU, HI, CA (northern) 38.4 30.1 -8.3 
15 AZ, CO, NM, NV, UT, WY 28.6 35.7 7.1 
11 MI, MN, ND, SD, WI 31.7 36.5 4.8 
18 CA (southern) 38.2 36.6 -1.6 
12 IA, KS, MO, NE 35.9 38.6 2.7 
2 NY 39.6 40.3 0.7 
5 DC, MD, VA, WV 29.0 42.9 13.9 
3 NJ, PR 35.6 45.0 9.4 
9 IN, KY, OH 33.2 45.7 12.5 
4 DE, PA 56.3 47.3 -9.0 
10 IL 44.3 49.5 5.2 
1 CT, MA, ME, NH, RI, VT 57.7 62.1 4.4 
All 29.8 34.1 4.3 
AS denotes American Samoa, GU denotes Guam.
 
Rows are sorted by percent reporting VRE in 1999.
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Human Immunodeficiency Virus Infection 
During 1985-1999, the percentage of centers that reported providing dialysis for patients 
with HIV infection increased from 11% to 36% (Table 22). Since a minority of centers routinely 
test for HIV, these figures may be underestimates. Note that the survey questions on HIV 
infection and AIDS were changed for the 1999 survey. In 1985-1997, the percent of patients with 
HIV infection was calculated as the number of patients with HIV infection who were treated at 
any time during the year divided by the total number of patients who were treated at any time 
during the year. In 1999, the percent of patients with HIV infection was calculated as the number 
of patients with HIV infection who were present during a one-week period in December divided 
by the total number of patients who were present during the same one-week period in December. 
Similar method was used to calculate the percent of patients with AIDS during 1985-1997 vs 
1999. 
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Table 22. Chronic Hemodialysis Centers Reporting Patients with HIV Infection, 1985-1999, United States 
Year 
No. (%) of 
Centers Treating Patients with 
HIV Infection 
No. (%) of 
Patients with 
HIV Infection 
No. (%) of 
Patients with 
Clinical AIDS 
1985 134 (11) 244 (0.3) -
1986 238 (18) 546 (0.6) 332 (0.4) 
1987 351 (24) 924 (1.0) 462 (0.5) 
1988 401 (25) 1,253 (1.2) 670 (0.6) 
1989 456 (26) 1,248 (1.0) 663 (0.5) 
1990 493 (26) 1,533 (1.1) 739 (0.5) 
1991 601 (29) 1,914 (1.2) 967 (0.6) 
1992 737 (34) 2,501 (1.5) 1,126 (0.7) 
1993 792 (34) 2,780 (1.5) 1,350 (0.7) 
1994 914 (37) 3,144 (1.5) 1,593 (0.8) 
1995 1,022 (39) 3,090 (1.4) 1,606 (0.7) 
1996 1,088 (39) 3,112 (1.4) 1,512 (0.7) 
1997 1,214 (39) 3,298 (1.3) 1,501 (0.6) 
1999* 1,241 (36) 3,223 (1.4) 1,077 (0.5) 
* Methods changed in 1999 (see text). 
35 
In 1999, 1.4% (range among the networks, 0.4%-3.1%) of patients were reported to have 
HIV infection and 0.5% (range among the networks, 0.1%-1.0%) to have AIDS (Table 23). 
Table 23. Chronic Hemodialysis Centers Reporting Patients with HIV Infection/AIDS, by End Stage Renal Disease 
(ESRD) Network, 1999, United States 
ESRD 
Network 
States, Districts, or Territories Number of Centers Number of 
Patients 
Percent of Patients With 
HIV 
Infection 
AIDS 
2 NY 193 17,041 3.1 1.0 
3 NJ, PR 111 10,331 2.8 1.0 
5 DC, MD, VA, WV 250 14,637 3.1 0.8 
7 FL 229 13,205 2.2 0.8 
4 DE, PA 188 10,965 1.7 0.6 
6 GA, NC, SC 325 20,418 1.7 0.6 
1 CT, MA, ME, NH, RI, VT 119 8,284 1.5 0.4 
8 AL, MS, TN 243 13,011 0.9 0.4 
14 TX 257 18,825 0.9 0.4 
17 AS, GU, HI, CA (northern) 137 11,283 1.0 0.4 
10 IL 109 9,841 1.2 0.3 
11 MI, MN, ND, SD, WI 256 13,401 0.7 0.3 
13 AR, LA, OK 222 10,330 1.1 0.3 
9 IN, KY, OH 243 15,967 0.6 0.2 
12 IA, KS, MO, NE 161 7,142 0.6 0.2 
18 CA (southern) 195 16,774 0.5 0.2 
15 AZ, CO, NM, NV, UT, WY 141 8,235 0.3 0.1 
16 AK, ID, MT, OR, WA 100 5,474 0.4 0.1 
All 3,483 225,226 1.4 0.5 
AS denotes American Samoa, GU denotes Guam. 
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U.S. DEPARTMENT OF HEALTH Appendix I
& HUMAN SERVICES Centers 
for Disease Control National Surveillance of Dialysis-Associated Diseases, 1999
and Prevention (CDC) For the Time Period January 1, 1999-December 31, 1999
Atlanta, Georgia 30333 
If you did not treat chronic non-transient in-center hemodialysis patients in 1999, do not fill out this form 
OMB NO.0920-0033 Exp.Date: 09/30/2002 
(5-10) Provider Number Name of Facility 
Present Address City State Zip Code 
PATIENT DATA 
1. How often does your facility routinely test seronegative (i.e., negative for hepatitis B surface antigen and hepatitis B surface antibody) patients for hepatitis B
 surface antigen (HBsAg)? (14-15) 
0 GNo routine testing 1 G Every month 2 G Every 2 months 
3 G Every 3-6 months 4 G Every 7-12 months 5 GOther (specify)__________________________________________________ 
2. Which of these best describes your center’s policy for hepatitis B vaccination of patients: (choose one) (16-17) 
1 GOffer vaccine to patients 2 G Vaccine is offered to patients at individual physician’s office 
3 GDo not offer vaccine to patients 4 GOther, specify___________________________________________________ 
3. During 1999 did your facility offer the pneumococcal pneumonia vaccine to chronic in-center hemodialysis patients?. . . . . . . . . . . . . . . (18) 1G Yes 2GNo 
3a. If Yes, what percent of the chronic hemodialysis patients assigned to your center as of December 6-11, 1999, have in the last five years received the pneumococcal 
pneumonia vaccine? 
(19) 1 G less than 25%  2 G  25-49%  3 G  50-74% 4 G 75-100% 5 GUnknown 
4. During 1999 did your facility offer the influenza (flu) vaccine to chronic in-center hemodialysis patients?. . . . . . . . . . . . . . . . . . . . . . . . . . (20) 1G Yes 2 GNo 
4a. If Yes, what percent of the chronic hemodialysis patients assigned to your center as of December 6-11, 1999, received the influenza (flu) vaccine during 1999? 
(21) 1 G less than 25%  2 G  25-49%  3 G  50-74% 4 G 75-100% 5 GUnknown 
5. During 1999, how many of your CHRONIC, NON-TRANSIENT in-center hemodialysis PATIENTS converted from hepatitis B surface
 ANTIGEN  (HBsAg) negative to positive  (i.e. had newly acquired hepatitis B virus infection. Do not include patients who were antigen
 positive before they were first dialyzed in your center)? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (22-24) ____________ 
6. How many CHRONIC, NON-TRANSIENT in-center hemodialysis PATIENTS were assigned to your center as of December 6-11, 1999? (25-27) ____________ 
6a. Of the patients counted in question 6, how many had ever in their lives received at least 3 doses of hepatitis B vaccine? . . . . . . (28-30) ____________ 
6b. Of the patients counted in question 6, were all or almost all tested for hepatitis B surface ANTIBODY (anti-HBs) during 1999? (31) 1 G Yes 2G No 
6b1) If Yes, how many were positive? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (32-34) ____________ 
6c. Of the patients counted in question 6, how many were hepatitis B surface antigen (HBsAg) positive?. . . . . . . . . . . . . . . . . . . . . . (35-37) ____________ 
7. Of the patients counted in question 6, were all or almost all tested for hepatitis C antibody during 1999?. . . . . . . . . . . . . . . . . . . . . . (38)
 (Note-this is NOT hepatitis B core antibody) 
1 G Yes 2GNo 
7a. If Yes, how many were positive for hepatitis C antibody? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (39-41) ____________ 
7b. If Yes, did any test positive for hepatitis C antibody in 1999 who had previously tested negative? . . . . . . . . . . . . . . . . . . . . . (42) 1 G Yes 2GNo 
8. During December 6-11, 1999, how many of your chronic hemodialysis 
PATIENTS received hemodialysis through: 
( Note: these numbers should add up to the number of patients in #6) 
8a. AV graft . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (43-45) ___________ 
8b. AV fistula . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (46-48) ___________ 
8c. Cuffed catheter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (49-51) ___________ 
8d. Non-cuffed catheter . . . . . . . . . . . . . . . . . . . . . . . . . . (52-54) ___________ 
9. Of the patients with catheters (questions 8c and 8d above), how many are in each of the following categories: 
(Total should be the same as the number of catheter patients reported in 8c and 8d above ): 
New hemodialysis patient, awaiting fistula/graft . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (55-57) ___________ 
Established patient, fistula/graft failed, new fistula/graft planned. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (58-60) ___________ 
Established patient, fistula/graft placement impossible–catheter is only available access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (61-63) ___________ 
Other, specify_______________________________________________________________________________________________ (64-66) ___________ 
Public reporting burden of this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and 
reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden 
estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Project Clearance Officer, 1600 Clifton Road, MS D-24, Atlanta, GA 30333, ATTN.: PRA (0920-0033). Do not send the 
completed form to this address. 
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DIALYSIS POLICIES AND PRACTICES 
10. During December 6-11, 1999, how many of your hemodialysis patients were treated with these dialyzer types: (write in the number of patients) 
a. High flux polysulfone (e.g. F60-F80) . . . . . . . . . . . . (67-69)  ____________ e. Cellulose triacetate (e.g. BaxterCT) .. . . 
b. Regenerated cellulose, cuprophane (e.g. TerumoCL-CT, 
AsahiAM, BaxterCF, Gambro-Lundia) . . . . . . . . . . (70-72) ____________ f. Hemophan (e.g. FoCus) . . . . . . . . . . . . 
c. Low flux polysulfone (e.g. F5-F8) . . . . . . . .. . . . . . . (73-75)  ___________ g. PMMA (e.g. Toray) . . . . . . . . . . . . . . 
d. Cellulose acetate
 (e.g. BaxterCA110-210, AlthinMCA) . . . . . . . . . . . . (76-78)  ___________ 
h. Other (specify) 
_______________________ 
(79-81) ____________ 
(82-84) ____________ 
(85-87) ____________ 
(88-90) ____________ 
11. In 1999, did your facility reuse dialyzers for some or all patients?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (91) 1G Yes 2G No 
If Yes: 
11a. What method is used to disinfect the majority of these dialyzers? (CHOOSE ONE) (92-93) 
1 G Formaldehyde (formalin) 2 G Glutaraldehyde (Diacide) 
3 G Peracetic acid (e.g., Renalin, and others) 4 GHeat 
5 G Amuchina 6 GOther (SPECIFY)________________________________________________ 
11b. Is bleach also used to clean the inside of these dialyzers?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (94) 1G Yes 2G No 
11c. Does your facility’s policy allow dialyzer reuse on patients who are positive for hepatitis C antibody (anti-HCV)? 
(95-96) 1 G Yes 2G No 3 GDo not have any known anti-HCV positive patients 
(Note: CDC guidelines permit dialyzer reuse for hepatitis C antibody-positive patients.) 
12. At your center, where are medications from multidose vials most commonly drawn into syringes to prepare for patient administration?  (CHOOSE ONLY ONE) 
1 G In a separate medication room or in a medication area separate from the dialysis stations  (97-98) 
2 G At the dialysis stations 
3 GOn a medication cart which is wheeled from patient dialysis station to dialysis station 
DISEASES OR COMPLICATIONS 
13. During the year 1999, how many of your hemodialysis patients were known to have a positive culture for vancomycin-resistant enterococcus (VRE)?
 (99) 0 G None 1 G 1-4 2 G 5-9 3 G$10 
13a. If you treated VRE-positive patients, do you treat them in a room separate from VRE-negative patients?
 (100) 0 G Never 1 G Sometimes 2G Always 
14. During 1999 did you perform rectal swabs or stool cultures on some patients to check for VRE at your center?
 (Do not include cultures done while a patient was hospitalized) (101) 1 G Yes 2G No 
15. During the year 1999 did any of your hemodialysis patients have a positive culture for methicillin-resistant Staphylococcus aureus (MRSA)? 
(102) 1 G Yes 2G No 
16. How many hemodialysis patients were treated with IV vancomycin during the MONTH of December 1999?
 (Write in number of patients treated, NOT number of doses of vancomycin) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (103-105) ____________ 
17. At your center, has there been an attempt to insure that antibiotics are used appropriately? (106) 1 G Yes 
If Yes, circle all measures that have been implemented: (107-112) 
2G No 
1 G  A written policy on antibiotic use 2 GReason for antibiotic must be recorded in chart or on order form 
3 G Automatic stop order (antibiotic must be reordered at intervals) 4 G Approval needed for use of certain antibiotics 
5 G  Formulary restriction (only selected antibiotics are available) 6 GOther, specify_________________________________________________ 
18. Among the chronic hemodialysis patients assigned to your center as of December 6-11, 1999, how many were known positive for HIV
 antibody? Include only chronic in-center hemodialysis patients  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (113-115) ___________ 
18a. Of these HIV antibody positive patients, how many were known to have AIDS? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (116-118) ___________ 
STAFF MEMBERS 
19. How many full-time and part-time staff were employed in your facility the week of December 6-11, 1999? Include only staff who had
      direct contact with hemodialysis patients or equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (119-121) ___________ 
19a. How many of these staff had ever in their lives received at least 3 doses of hepatitis B vaccine? . . . . . . . . . . . . . . . . . . . . . . (122-124) ___________ 
19b. Were all or almost all of these staff tested for hepatitis C antibody (anti-HCV) during 1999?. . . . . . . . . . . . . . . . . . . . . . . . (125) 
(Note-this is not hepatitis B core antibody) 
1 G Yes 2GNo 
19b1) If Yes, how many were positive for hepatitis C antibody?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . (126-128) ___________ 
Comments: 
NAME OF PERSON WHO COMPLETED THIS SURVEY 
Please PRINT: ................................................................................................................., .................................................................................................. 
LAST NAME (129-139) FIRST NAME (140 -150) 
Phone: ( ___ ___ ___ ) ___ ___ ___ -- ___ ___ ___ ___ Fax: ( ___ ___ ___ ) ___ ___ ___ -- ___ ___ ___ ____ 
(151-160) (161 -170) 
Send Copy 1 of the completed form to your ESRD Network office. Keep Copy 2 for your own records. DO NOT SEND FORM TO CDC. 
Call Elaine Miller (404-639-6422) with questions. Use of trade names is for identification only and does not constitute endorsement by the Public Health Service or the U.S. Department of Health and Human Services. 
CDC 53.7 Rev 10/99 (2 of 2) Copy 1 - CDC 
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Appendix II 
Recommended Infection Control Practices for Hemodialysis Units 
Infection control precautions for all hemodialysis patients (A1) 
! Wear disposable gloves when caring for the patient or touching the patient’s equipment at the 
dialysis station; remove gloves and wash hands between each patient or station. 
! Items taken into the dialysis station should either be disposed of, dedicated for use only on a 
single patient, or cleaned and disinfected before taken to a common clean area or used on 
another patient. 
" Nondisposable items that cannot be cleaned and disinfected (e.g., adhesive tape, cloth-
covered blood pressure cuffs) should be dedicated for use only on a single patient. 
" Unused medications (including multiple dose vials containing diluents) or supplies 
(syringes, alcohol swabs, etc.) taken to the patient’s station should be used only for that 
patient and should not be returned to a common clean area or used on other patients. 
! When multiple dose medication vials are used (including those containing diluents), prepare 
individual patient doses in a clean (centralized) area away from dialysis stations and deliver 
separately to each patient. Do not carry multiple dose medication vials from station to station. 
! Do not use common medication carts to deliver medications to patients. Do not carry 
medication vials, syringes, alcohol swabs or supplies in pockets. If trays are used to deliver 
medications to individual patients, they must be cleaned between patients. 
! Clean areas should be clearly designated for the preparation, handling and storage of 
medications and unused supplies and equipment. Clean areas should be clearly separated from 
contaminated areas where used supplies and equipment are handled. Do not handle and store 
medications or clean supplies in the same or an adjacent area to that where used equipment or 
blood samples are handled. 
! Use external venous and arterial pressure transducer filters/protectors for each patient treatment 
to prevent blood contamination of the dialysis machines’ pressure monitors. Change 
filters/protectors between each patient treatment, and do not reuse them. Internal transducer 
filters do not need to be changed routinely between patients. 
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!	 Clean and disinfect the dialysis station (chairs, beds, tables, machines, etc.) between patients. 
"	 Give special attention to cleaning control panels on the dialysis machines and other 
surfaces that are frequently touched and potentially contaminated with patients' blood. 
"	 Discard all fluid and clean and disinfect all surfaces and containers associated with the 
prime waste (including buckets attached to the machines). 
!	 For dialyzers and blood tubing that will be reprocessed, cap dialyzer ports and clamp tubing. 
Place used dialyzer and tubing in a leak-proof container for transport from station to 
reprocessing or disposal area 
Hepatitis B vaccination (A1, A2) 
!	 Vaccinate all susceptible patients against hepatitis B. 
! Test for anti-HBs 1-2 months after last dose 
" if anti-HBs <10 mIU/mL, consider susceptible, revaccinate with an additional three 
doses, and retest for anti-HBs; 
" if anti-HBs >10 mIU/mL, consider immune and retest annually give booster dose of 
vaccine if anti-HBs <10 mIU/mL and continue to retest annually. 
Management of HBsAg-positive patients (A1)
 
! Infection control practices for hemodialysis units for all patients.
 
! Dialyze HBsAg-positive patients in a separate room using separate machines, equipment,
 
instruments, and supplies. 
!	 Staff members caring for HBsAg-positive patients should not care for HBV susceptible patients 
at the same time (e.g., during the same shift or during patient change-over). 
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Routine serologic testing for hepatitis B virus (HBV) and hepatitis C virus (HCV) (A1) 
Patient Status 
On 
Admission Monthly 
Semi-
Annual Annual 
All patients HBsAg*, Anti-HBc (total) 
Anti-HBs, Anti-HCV, ALT 
HBV susceptible, including 
non-responders to vaccine 
HBsAg 
Anti-HBs positive (>10 
mIU/mL), anti-HBc negative 
Anti-HBs 
Anti-HBs and anti-HBc 
positive 
No additional HBV testing needed 
Anti-HCV negative ALT Anti-HCV 
* Results of HBsAg testing should be known before the patient begins dialysis. 
Other infection control topics 
!	 Guidelines for vascular access use and preventing access-associated infections (A3, A4). 
!	 Chronic hemodialysis patients should receive pneumococcal vaccine every 5 years and 
influenza vaccine every year (A5). 
!	 Recommendations for prudent vancomycin use have been made by CDC and the Hospital 
Infection Control Practices Advisory Committee (A6). Cefazolin, a first-generation 
cephalosporin, may be substituted for vancomycin in some instances (A7). 
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Appendix III 
DIALYSIS SURVEILLANCE NETWORK 
The Dialysis Surveillance Network (DSN), a voluntary national surveillance system monitoring 
bacterial infections and related events in hemodialysis patients, was initiated by CDC in August 
1999. Both adult and pediatric dialysis centers treating outpatients are invited to participate. 
Bacterial infections, especially those involving the vascular access site, cause considerable 
morbidity and mortality in hemodialysis patients. Due to frequent hospitalizations and receipt of 
antimicrobials, these patients are at high risk for infection or colonization with antimicrobial-
resistant bacteria. However, there are few recent studies of bacterial infections in hemodialysis 
patients, and previously there were no standardized surveillance methods. 
The purposes of the DSN are as follows: 
1.	 To provide a method for individual hemodialysis centers to record and track rates of 
vascular access infections, other bacterial infections, and intravenous antimicrobial starts. 
2.	 To provide rates for comparisons among various dialysis centers (benchmarking). 
3.	 To use these data to motivate practice changes and to prevent infections, especially those 
caused by antimicrobial resistant organisms. 
Participating centers may enter data on paper forms provided by CDC and receive a data 
analysis report every quarter. Alternatively, they may use our Internet-based system for data 
entry and analysis and generate and print reports whenever desired. While summary data are 
released, the data from individual centers are confidential and cannot be released to anyone other 
than the dialysis center reporting the data. 
Unique features of the DSN include: 
!	 User-friendly methods simplify reporting. 
!	 Data collectors record the presence or absence of criteria for infections, not the infections 
themselves. 
!	 A computer algorithm determines whether the infection case definitions are met. 
!	 The data collector does not have to memorize case definitions. 
!	 The frequency of blood culturing, a factor that may influence reported infection rates, is 
determined. 
!	 Several different rates are reported to better characterize the situation at any given center. 
Centers are encouraged to participate in this system as a quality monitoring and control measure. 
For information about enrollment, call 404-639-6422 or go to 
http://www.cdc.gov/ncidod/hip/Dialysis/procedure.htm 
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SAMPLE DATA: DIALYSIS SURVEILLANCE NETWORK
 
The graph below shows some sample data from this surveillance system. The rates for “All 
Centers” are compared with the rate at a single center, designated “Center X.” Data are shown as 
the rate per 100-patient months, which is equivalent to the percent of patients having the stated 
event each month. 
The five events in the graph include hospitalization, outpatient IV antimicrobial starts, outpatient 
IV vancomycin starts, access-related bacteremia (i.e., positive blood cultures thought to be related 
to the patient’s vascular access device), and vascular access infection (i.e., includes episodes both 
with and without a positive blood culture). 
As indicated by the asterisk (*), “Center X” has some rates that are significantly higher than other 
centers. This was determined after standardizing the data, i.e., accounting for any possible 
differences in the mix of vascular access types between Center X and other centers1. We hope that 
these comparisons will assist dialysis centers in their attempts to reduce infections, use 
antimicrobials wisely, and limit the spread of antimicrobial resistance. 
1Infection rates vary widely depending on the type of vascular access. For example, the rate of access-related 
bacteremia was 0.22 per 100 patient-months for fistulas, 0.48 for grafts, 5.25 for noncuffed catheters, and 8.85 for 
cuffed catheters 
